ARTICLES BY MARCUS JOHNSON
Domestic Prices Of Bulk Drugs From India Likely To Increase This Year
The growth of bulk drugs exported from India has slowed in recent months, due to regulatory questions from the U.S. and the EU. However, the price of bulk drugs is expected to increase in India this year.
Indian Based Lupin Pharmaceuticals Exploring U.S. Expansion
Lupin, the Indian drug manufacturer based out of Mumbai, has taken a new step to is expand its visibility in the U.S.
Novartis Closes Trial For Heart Failure Drug Due To Strong Results
In a press release last week, Novartis announced that the Data Monitoring Committee unanimously recommended an early closure of the PARADIGM-HF study testing the Angiotensin Receptor Neprilysin Inhibitor (ARNI), LCZ696.
Express Scripts Pressuring Gilead To Lower Price For Hepatitis C Drug
Express Scripts, the pharmacy benefit manager that processes more than 1 billion prescriptions each year, is putting pressure on Gilead Sciences to lower the price of their hepatitis C drug, Sovaldi.
Meda Turns Down Merger Offer From Mylan
Meda has announced that it has rejected a merger offer from generic pharmaceutical company Mylan.
Mallinckrodt To Acquire Questcor And Its MS Drug
Mallinckrodt Pharmaceuticals is set to acquire Questcor Pharmaceuticals for $5.6 billion in cash and stock.
Auto-Injector Used To Treat Opioid Overdose Approved By FDA
Earlier last week, the FDA approved Evzio (naloxone hydrochloride injection), which can be administered to patients suffering from an opioid overdose via a hand-held auto injector.
FDA Advisory Panel Calls Mannkind Diabetes Drug Safe
The FDA's advisory panel voted in favor of backing the inhaled diabetes drug Afrezza produced by Mannkind Corp.
Novartis Replacing Executives In Japanese Unit
The Swiss based pharmaceutical company Novartis has announced that it will be replacing lead executives from its Japanese unit. The company's Japanese unit has faced allegations from the Japanese government that the company falsified research data and hid the potentially dangerous side effects of its leukemia drug from the medical community and state regulators.
MS Drug Linked As Possible Cause Of Thrombotic Microangiopathy
In a letter in the March 27th issue of the New England Journal of Medicine, Scottish researchers announced that they’d found evidence linking the MS drug Rebif to the formation of “thrombotic microangiopathy.” This condition causes serious blood clots to form in small blood vessels in different parts of the body. The condition is rare, but it is potentially life threatening.